Table 3.

Effect of baseline polymorphisms on occurrence of D30N substitutiona

Amino acid positionNo. of patients with D30N substitution (%)P valueb
Polymorphism absentPolymorphism present
1022/47 (46.8)3/8 (37.5)0.715
1220/43 (46.5)5/12 (41.7)1.000
1319/42 (45.2)6/13 (46.2)1.000
1519/42 (45.2)6/13 (46.2)1.000
3517/43 (39.5)8/12 (66.7)0.114
3619/40 (47.5)6/15 (40.0)0.764
3719/40 (47.5)6/15 (40.0)0.764
4123/45 (51.1)2/10 (20.0)0.092
6220/41 (48.8)5/14 (35.7)0.537
637/14 (50.0)18/41 (43.9)0.762
6417/43 (39.5)8/12 (66.7)0.114
7222/47 (46.8)3/8 (37.5)0.715
7719/40 (47.5)6/15 (40.0)0.763
9320/44 (45.5)5/11 (45.5)1.000
• a Sequence analysis was performed on HIV protease genes obtained from plasma samples from 55 patients at baseline prior to nelfinavir therapy. Polymorphisms which occurred in >10% patients (≥6 changes/55 baseline sequences) were identified based on comparison with the consensus sequence as described in Materials and Methods. The proportion of patients that acquired the D30N substitution following nelfinavir therapy was then calculated for each of the two groups (polymorphism absent or present).

• b A test of equality of the two proportions was conducted by Fisher’s exact test.